ArticleHereditas2026
E2F2 and TFDP1 as novel systemic lupus erythematosus (SLE) diagnostic markers and therapeutic targets based on machine learning and experimental study.
Article in Hereditas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- The application of artificial intelligence in systemic lupus erythematosus: a bibliometric analysis of current trends and future directions.Frontiers in medicine · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSystemic lupus erythematosus (SLE) is a chronic autoimmune disease influenced by multiple genetic and environmental factors.. This study used bioinformatics to identify new diagnostic biomarkers and explore the pathogenesis of SLE.
methodThree array datasets of peripheral blood mononuclear cells (PBMCs) from SLE patients and control subjects were obtained from GEO, including GSE82221 and GSE11909 (merged for feature discovery) and GSE154851 (independent validation/machine learning training dataset). RRA analysis was used to identify statistically changed DEGs. GO and KEGG analyses explored biological mechanisms. Consistent clustering and machine learning models were employed to identify diagnostic biomarkers, further assessed using ROC and DCA analysis. The proportions of 22 immune cells in SLE patients were calculated via CIBERSORT algorithm, and correlations between biomarkers and immune cells were explored. Data from 76 clinical blood samples were collected, including ALT, AST, CR, BUN, CRP, PLT, WBC, lymphocyte (%), and neutrophil (%). RT-qPCR was used to validate the expression of diagnostic biomarkers.
resultsA total of 62 DEGs were identified, mainly involved in the cell cycle and TGF-beta signaling pathway. Six candidate diagnostic biomarkers for SLE were found: E2F2, KIAA0319L, TRIM58, MMP8, FKBP5, and TFDP1. E2F2 and TFDP1 showed AUC values > 0.7 in training and validation datasets. CIBERSORT analysis revealed disturbed immune cell types in SLE patients, with plasma cells most relevant to E2F2 and TFDP1 expression. Expression of E2F2 and TFDP1 was upregulated in patient samples. The diagnostic models, including E2F2 and TFDP1, performed better than those without these biomarkers.
conclusionOur study identifies E2F2 and TFDP1 as potential diagnostic biomarkers for SLE patients and uncovers their most relevant immune cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.